Volume 26, Number 6—June 2020
Research
Characterization of Sporadic Creutzfeldt-Jakob Disease and History of Neurosurgery to Identify Potential Iatrogenic Cases
Table 1
Comparison of the clinical features of patients with Creutzfeldt-Jakob disease with and without history of neurosurgery*
Patient characteristics | Neurosurgery | No neurosurgery | p value |
---|---|---|---|
Total no. patients |
27 |
1,128 |
|
Sex, no. (%) | |||
F | 17 (63.0) | 647 (57.4) | 0.353 |
M |
10 (37) |
481 (42.6) |
|
Age at onset, y + SD (range) | 71.0 + 8.8 (49–88) | 68.7 + 9.6 (30–91) | 0.217 |
Disease duration, mo + SD (range)† | 6.1 + 7.8 (1–28) | 6.7 + 12.0 (0–171) | 0.823 |
Duration from neurosurgery to onset of CJD, y + SD (range) |
15.0 + 9.1 (1–35) |
||
Polymorphism at codon 129 of prion protein gene, no. (%) | |||
MM | 25 (92.6) | 1,101 (97.6) | 0.138 |
MV | 2 (7.4) | 22 (1.9) | |
VV |
0 |
5 (0.4) |
|
Negative rate of PSWCs on EEG, no. (%) | 5 (18.5) | 64/1,121 (5.7) | 0.019 |
14-3-3 protein in CSF, no. tested/no. positive (%) | 20/22 (90.9) | 675/803 (84.1) | 0.300 |
Tau protein in CSF, cutoff 1,200 pg/mL, no. tested/no. positive (%) | 13/14 (92.9) | 503/567 (88.7) | 0.523 |
*CJD, Creutzfeldt-Jakob disease; CSF, cerebrospinal fluid; EEG, electroencephalogram; PSWCs, periodic sharp-wave complexes
†Disease duration of CJD: duration between the onset of CJD and the appearance of the akinetic mutism or death in the patients who died without akinetic mutism
Page created: May 18, 2020
Page updated: May 18, 2020
Page reviewed: May 18, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.